Rejuvenation Res. 2011 Aug;14(4):457-61. doi: 10.1089/rej.2011.1237.
Dr. William H. Andrews has worked in the biotech industry for 31 years, focusing the last 19 years on finding ways to extend human life span through the intervention of telomere shortening in human cells. Dr. Andrews earned his Ph.D. in Molecular and Population Genetics at the University of Georgia. He was a Senior Scientist at Armos Corporation and Codon Corporation, Director of Molecular Biology at Codon and at Geron Corporation, and Director of Technology Development at EOS Biosciences. He is presently the founder, President, and CEO of Sierra Sciences, a biotechnology company focused exclusively on finding drugs that will transiently induce the expression of endogenous telomerase in human cells. Sierra Sciences has already identified more than 30 such drugs and is presently characterizing their mechanism of action. While Director of Molecular Biology at Geron Corporation, Dr. Andrews was one of the principal discoverers of both the RNA and protein components of human telomerase and was awarded second place as "National Inventor of the Year" in 1997 for this work. He is presently a named inventor on 43 U.S- issued telomerase patents.
威廉·H·安德鲁斯博士在生物技术行业工作了 31 年，过去 19 年的重点是通过干预人类细胞中端粒缩短来延长人类寿命。安德鲁斯博士在佐治亚大学获得了分子和群体遗传学博士学位。他曾是 Armos 公司和 Codon 公司的高级科学家，Codon 和 Geron 公司的分子生物学主任，以及 EOS 生物技术公司的技术开发主任。他目前是 Sierra Sciences 的创始人、总裁兼首席执行官，该生物技术公司专门致力于寻找可暂时诱导人类细胞内内源性端粒酶表达的药物。Sierra Sciences 已经确定了 30 多种此类药物，目前正在描述它们的作用机制。在 Geron 公司担任分子生物学主任期间，安德鲁斯博士是人类端粒酶的 RNA 和蛋白质成分的主要发现者之一，并因这项工作获得 1997 年“年度国家发明家”第二名。他目前是 43 项美国授权的端粒酶专利的署名发明人。
